IQVIA Holdings Inc. $IQV Shares Acquired by Assetmark Inc.

Assetmark Inc. lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 127.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 117,261 shares of the medical research company’s stock after purchasing an additional 65,808 shares during the quarter. Assetmark Inc.’s holdings in IQVIA were worth $18,479,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Arkadios Wealth Advisors purchased a new stake in IQVIA in the second quarter valued at approximately $301,000. World Investment Advisors grew its stake in shares of IQVIA by 17.9% in the second quarter. World Investment Advisors now owns 78,747 shares of the medical research company’s stock valued at $12,410,000 after buying an additional 11,940 shares in the last quarter. Flagship Harbor Advisors LLC lifted its stake in IQVIA by 199.0% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 5,502 shares of the medical research company’s stock worth $867,000 after acquiring an additional 3,662 shares in the last quarter. Motco boosted its holdings in IQVIA by 13.3% during the 2nd quarter. Motco now owns 46,987 shares of the medical research company’s stock valued at $7,405,000 after acquiring an additional 5,511 shares during the period. Finally, Logan Capital Management Inc. grew its position in IQVIA by 5.0% in the 2nd quarter. Logan Capital Management Inc. now owns 15,541 shares of the medical research company’s stock valued at $2,449,000 after acquiring an additional 745 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by company insiders.

IQVIA Stock Performance

Shares of IQV stock opened at $216.43 on Friday. The company has a market cap of $36.86 billion, a P/E ratio of 29.69, a PEG ratio of 2.43 and a beta of 1.32. The firm has a fifty day moving average price of $197.12 and a 200 day moving average price of $173.77. The company has a current ratio of 0.70, a quick ratio of 0.84 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $225.91.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.IQVIA’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on IQV. JPMorgan Chase & Co. increased their price target on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Cowen restated a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Truist Financial reiterated a “buy” rating and issued a $265.00 price objective (up from $235.00) on shares of IQVIA in a research note on Wednesday. Finally, Baird R W raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $241.41.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.